Treatment results with the breast cancer drug Herceptin, as well as chemotherapy, did improve,...
TRACON Pharmaceuticals, a clinical stage biopharmaceutical company, today announced its...
If the Supreme Court rules the way most Republicans want in the latest health overhaul case, GOP...
Vitae Pharmaceuticals, a clinical-stage biotechnology company, recently provided financial results and pipeline reports for the first quarter of 2015.
The treatment market value for fibromyalgia across the seven major markets will reach $1.9 billion by 2023, according to research and consulting firm GlobalData.
Novavax, Inc., a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced Q1 results.
Portola Pharmaceuticals today provided a corporate update and reported its financial results for the first quarter.
The global market for Alzheimer’s Disease treatment will more than double in value from $4.9 billion in 2013 to reach an estimated $13.3 billion by 2023.
Amyris, Inc., the industrial bioscience company, today announced financial results for the first quarter of 2015.
Sagent Pharmaceuticals, Inc., a maker of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced financial results for the first quarter.
AMAG Pharmaceuticals, Inc., a specialty pharmaceutical company, today reported unaudited consolidated financial results for the first quarter of 2015.
Pharmaceutical processors face a number of challenges in determining the direction they should take when considering internal investments – but a lack of options have never been amongst them.
Sac-Osage is one of a growing number of rural U.S. hospitals closing their doors, citing a complex combination of factors that have put more financial pressure on facilities.
The most-used medicines in Medicare's prescription drug program are generics, but the program spends the most on brand-name drugs, led by the heartburn treatment Nexium.
TESARO, Inc., an oncology-focused biopharmaceutical company, today reported operating results for first-quarter 2015 and provided an update on the Company's development programs.
The global treatment market value for prostate cancer will expand more than threefold by 2023.
Flexion Therapeutics announced a DoD grant for a clinical trial investigating FX006 as treatment for osteoarthritis ("OA") pain in military personnel.
Epigenomics AG today announced that the Company will receive an EU grant under the industrial leadership Horizon 2020 research and innovation program.
Mylan N.V. today announced that it has increased its offer to acquire the issued and to be issued shares of Perrigo.
Anglo-Swedish drug-maker AstraZeneca PLC reported a 7 percent fall in net profit for the first quarter of 2015, as cheaper copies of one of its best-sellers ate into sales.
Shares of Aerie Pharmaceuticals lost two-thirds of their value in after-market trading after the company said its experimental eye pressure drug Rhopressa failed in a late-stage clinical trial.
Swiss-based pharmaceutical company Novartis reported a large jump in first-quarter net profit Thursday as it recorded one-time gains from deals with other drug companies.
The Roche Group posted strong sales growth in the first three months in both divisions, with demand for oncology and immunology medicines driving growth in pharmaceuticals, and immunodiagnostics products driving growth in diagnostics.
A company with deep roots at the University of Wisconsin-Madison wants to make blood sampling less painful and more convenient.
Innocrin Pharmaceuticals is developing small-molecule CYP17 lyase-selective inhibitors to treat resistant hormonally-dependent breast and prostate cancers.
$2.0 million of preferred stock will be purchased upon Synthonics’ achievement of certain milestones, which could be expected during 2016.
GlobalData’s Healthcare Industry Analyst says the rise in biotech peer group total revenue over the past year was driven by Regeneron and Alexion, both of which posted sales of more than $2 billion in 2014.
Cuts to global health research budgets and people’s wariness of vaccines could hamper efforts to improve health around the world.
- Page 1